Altered intravenous pharmacokinetics of topotecan in rats with acute renal failure (ARF) induced by uranyl nitrate: Do adenosine A₁ antagonists (selective/non-selective) normalize the altered topotecan kinetics in ARF?

References

• Ahn CY, Kim EJ, Lee I, Kwon JW, Kim WB, Kim SG, Lee MG. Effects of glucose on the pharmacokinetics of intravenous chlorzoxazone in rats with acute renal failure induced by uranyl nitrate. Journal of Pharmaceutical Sciences 2003; 92: 1604–1613
   PubMedGoogle Scholar
• Bae SK, Lee SJ, Kim JW, Kim YH, Kim SG, Lee MG. Effects of acute renal failure on the pharmacokinetics of oltipraz in rats. Journal of Pharmaceutical Sciences 2004; 93: 2353–2363
   PubMedGoogle Scholar
• Bellomo R, May C, Wan L. Acute renal failure and sepsis. New England Journal of Medicine 2004; 351: 2347–2349
   PubMedGoogle Scholar
• Bradford MA. Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein–dye binding. Analytical Biochemistry 1976; 72: 248–254
   PubMed Web of Science ®Google Scholar
• Brenner BM, Lazarus JM. Acute renal failure3rd. Churchill Livingstone, New York, NY 1992; 359–360
   Google Scholar
• Chung HC, Kim SH, Lee MG, Kim SG. Increase in urea in conjunction with L-arginine metabolism in the liver leads to induction of cytochrome P450 2E1 (CYP2E1): The role of urea in CYP2E1 induction by renal failure. Drug Metabolism and Disposition 2002; 30: 739–746
   PubMed Web of Science ®Google Scholar
• Chung WS, Kim EJ, Lee I, Kim SG, Lee MG, Kim SH. Effects of recombinant growth hormone on the pharmacokinetics of chlorzoxazone in rats with acute renal failure induced by uranyl nitrate. Life Sciences 2003; 73: 253–263
   PubMedGoogle Scholar
• Churchill PC, Bidani AK. Hypothesis: Adenosine mediates hemodynamic changes in renal failure. Medical Hypotheses 1982; 8: 275–285
   PubMed Web of Science ®Google Scholar
• Creemers GJ, Lund B, Verweij J. New drugs: Topoisomerase I inhibitors: Topotecan and irenotecan. Cancer Treatment Reviews 1994; 20: 73–96
   PubMed Web of Science ®Google Scholar
• Dennis MJ, Beijnen JH, Grochow LB, Van Warmerdam LJ. An overview of the clinical pharmacology of topotecan. Seminars in Oncology 1997; 24: S5-12–S5-18
   Google Scholar
• Engineer MS, Ho DH, Bodey Sr GP. Comparison of vancomycin disposition in rats with normal and abnormal renal functions. Antimicrobial Agents and Chemotherapy 1981; 20: 718–722
   PubMed Web of Science ®Google Scholar
• Fruncillo RJ, Swanson BN, Bernhard R, Marchion C, Ferguson RK. Effect of renal failure or biliary stasis on the pharmacokinetics of amiodarone in the rat. Journal Pharmaceutical Sciences 1986; 75(2)150–154
   PubMedGoogle Scholar
• Furman WL, Baker SD, Pratt CB, Rivera GK, Evans WE, Stewart CF. Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia. Journal of Clinical Oncology 1996; 14: 1504–1511
   PubMed Web of Science ®Google Scholar
• Gibaldi M, Perrier D. Pharmacokinetics2nd. Marcel Dekker, New York, NY 1982
   Google Scholar
• Gibson TP. Applied pharmacokinetics2nd. Applied Therapeutics, Washington, DC 1986; 83–115
   Google Scholar
• Gulyassy PF, Depner TA. Impaired binding of drugs and endogenous ligands in renal diseases. American Journal of Kidney Diseases 1983; 2: 578–601
   PubMed Web of Science ®Google Scholar
• Gupta M, Fujimori A, Tamhane AC. Eukaryotic DNA topoisomerases I. Biochimica Biophysics Acta 1995; 1262: 1–14
   PubMed Web of Science ®Google Scholar
• Henry JB. Clinical diagnosis and management by laboratory methods18th. W. B. Saunders, Philadelphia, PA 1991; 120–122
   Google Scholar
• Iven H, Brasch H. Influence of the antibiotics piperacillin, doxycycline, and tobramycin on the pharmacokinetics of methotrexate in rabbits. Cancer Chemotherapy and Pharmacology 1986; 17: 218–222
   PubMed Web of Science ®Google Scholar
• Kim SH, Shim HJ, Kim WB, Lee MG. Pharmacokinetics of a new carbapenem, DA-1131, after intravenous administration to rats with uranyl nitrate-induced acute renal failure. Antimicrobial Agents Chemotherapy 1998; 42: 1217–1221
   PubMedGoogle Scholar
• Lee AK, Lee JH, Kwon JW, Kim WB, Kim SG, Kim SH, Lee MG. Pharmacokinetics of clarithromycin in rats with acute renal failure induced by uranyl nitrate. Biopharmaceutics and Drug Disposition 2004; 25: 273–282
   PubMed Web of Science ®Google Scholar
• Lee W, Kim RB. Transporters and renal drug elimination. Annual Reviews in Pharmacology and Toxicology 2004; 44: 137–166
   PubMed Web of Science ®Google Scholar
• Lee YH, Lee MH, Shim CK. Decreased systemic clearance of diltiazem with increased hepatic metabolism in rats with uranyl nitrate-induced acute renal failure. Pharmaceutical Research 1992; 9: 1599–1606
   PubMed Web of Science ®Google Scholar
• Lindup WE, Henderson SJ, Barker CE. Plasma binding of drug and its consequence, F Belpaire, M Bogaert, JP Tillement, E Verbeeck. Academic Press, Ghent 1991; 103–120
   Google Scholar
• Lindup WE. Progress in drug metabolism, JW Bridges, LF Chasseaud, CG Gibson. Taylor & Francis, London 1987; 10: 141–185
   Google Scholar
• Liu JH, Malone RS, Stallings H, Smith PC. Influence of renal failure on the disposition of salicyl acyl glucuronide and covalent binding of salicylate to plasma proteins. Journal of Pharmacology and Experimental Therapeutics 1996; 278: 277–283
   PubMedGoogle Scholar
• Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clinical Pharmacology and Therapeutics 1995; 58: 641–649
   PubMed Web of Science ®Google Scholar
• Moon YJ, Lee AK, Chung HC, Kim EJ, Kim SH, Lee I, Kim SG, Lee MG. Effects of acute renal failure on the pharmacokinetics of chlorzoxazone in rats. Drug Metabolism and Disposition 2003; 31: 776–784
   PubMed Web of Science ®Google Scholar
• O’Reilly S, Rowinsky E, Slichenmyer W, Donehower RC, Forastiere A, Ettinger D, Chen T, Sartorius S, Bowling K, Smith J, Brubaker A, Lubejko B, Ignacio V, Grochow LB. Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function. Journal of National Cancer Institute 1996a; 88: 817–824
   PubMedGoogle Scholar
• O’Reilly S, Rowinsky E, Slichenmyer W, Donehower RC, Forastiere A, Ettinger D, Chen T, Sartorius S, Grochow LB. Phase I and pharmacologic study of topotecan in patients with impaired renal function. Journal of Clinical Oncology 1996b; 14: 3062–3073
   PubMed Web of Science ®Google Scholar
• Park JM, Moon CH, Lee MG. Pharmacokinetic changes of methotrexate after intravenous administration to uranyl nitrate-induced acute renal failure rats. Research Communications in Molecular Pathology and Pharmacology 1996; 93: 353–362
   PubMedGoogle Scholar
• Park KJ, Yoon WH, Kim SH, Shin WG, Lee MG. Pharmacokinetic and pharmacodynamic changes of azosemide after intravenous and oral administration of azosemide to uranyl nitrate-induced acute renal failure rats. Biopharmaceutics and Drug Disposition 1998; 19: 141–146
   PubMedGoogle Scholar
• Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chemical Research in Toxicology 1990; 6: 566–573
   Google Scholar
• Platzer P, Schaden S, Thalhammer T, Hamilton G, Rosenberg B, Silgoner I, Jager W. Biotransformation of topotecan in the isolated perfused rat liver: Identification of three novel metabolites. Anticancer Research 1998; 18: 2695–2700
   PubMedGoogle Scholar
• Potmesil M. Camptothecins: From bench research to hospital wards. Cancer Research 1994; 54: 1431–1439
   PubMed Web of Science ®Google Scholar
• Rao MNVS, Biju B, Ansar AK, Mujeeb S, Ramesh M, Srinivas NR. Open access generic method for continuous determination of major human CYP 450 substrates/metabolites and its application in drug metabolism studies. Xenobiotica 2003; 12: 1233–1245
   Google Scholar
• Sakai T, Maruyama T, Imamura H, Shimada H, Otagiri M. Mechanism of stereoselective serum binding of ketoprofen after hemodialysis. Journal of Pharmacology and Experimental Therapeutics 1996; 278: 786–792
   PubMedGoogle Scholar
• Schellens JH, Creemers GJ, Beijnen JH, Rosing H, de Boer-Dennert M, McDonald M, Davies B, Verweij J. Bioavailability and pharmacokinetics of oral topotecan: A new topoisomerase I inhibitor. British Journal of Cancer 1996; 73: 1268–1271
   PubMed Web of Science ®Google Scholar
• Sica DA, Lo MW, Shaw WC, Keane WF, Gehr TWB, Halstenson CE, Lipschutz K, Furtek CI, Ritter MA, Shahinfar S. The pharmacokinetics of losartan in renal insufficiency. Journal of Hypertension 1995; 13(Suppl. 1)S49–S52
   PubMedGoogle Scholar
• Slichenmyer WJ, Chen TL, Donehower RC, Sartorius S, Rowinsky E, Shifflett C, Bowling MK, Grochow L. Clinical pharmacology of topotecan in cancer patients with renal or hepatic dysfunction (abstract). Proceedings of Annual Meeting of American Society of Clinical Oncology 1994; 13: A363
   Google Scholar
• Stewart CF, Baker SD, Heideman RL, Jones D, Crom WR, Pratt CB. Clinical pharmacodynamics of continuous infusion topotecan in children: Systemic exposure predicts haematologic toxicity. Journal of Clinical Oncology 1994; 12: 1946–1954
   PubMed Web of Science ®Google Scholar
• Tagawa H, Sugimoto T, Saito H, Nishio K. The hypotensive effect and pharmacokinetics of MK-954 (losartan potassium) in hemodialysis patients with high blood pressure. Japan Journal of Clinical Dialysis 1995; 11: 247–264
   Google Scholar
• Underberg WJ, Goossen RM, Smith BR, Beijnen JH. Equilibrium kinetics of the new experimental anti-tumour compound SK&F 104864-A in aqueous solution. Journal of Pharmaceutical Biomedical Analysis 1990; 8: 681–683
   PubMed Web of Science ®Google Scholar
• Uwai Y, Saito H, Inui K. Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter. European Journal of Pharmacology 2000; 409: 31–36
   PubMed Web of Science ®Google Scholar
• Wall ME, Wani MC. Antineoplastic agents from plants. Annual Review of Pharmacology and Toxicology 1977; 17: 117–132
   PubMed Web of Science ®Google Scholar
• Yoshitani T, Yagi H, Inotsume N, Yasuhara M. Effect of experimental renal failure on the pharmacokinetics of losartan in rats. Biological and Pharmaceutical Bulletin 2002; 8: 1077–1083
   Google Scholar
• Yu SY, Chung HC, Kim EJ, Kim SH, Lee I, Kim SG, Lee MG. Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous theophylline in rats: The role of CYP2E1 induction in 1,3-dimethyluric acid formation. Journal of Pharmacy and Pharmacology 2002; 54: 1687–1692
   PubMed Web of Science ®Google Scholar
• Zamboni WC, Heideman RL, Meyer WH, Gajjar AJ, Crom WR, Stewart CF. Pharmacokinetics (PK) of topotecan in pediatric patients with normal and altered renal function (abstract). Proceedings of the American Society for Clinical Oncology 1996; 15: 371
   Google Scholar
• Zamboni WC, Houghton PJ, Johnson RK, Hulstein JL, Crom WR, Cheshire PJ, Hanna SK, Richmond LB, Luo S, Stewart CF. Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion. Journal of Pharmacology and Experimental Therapeutics 1998; 284: 89–94
   PubMedGoogle Scholar